Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
74.95
-0.59 (-0.78%)
At close: May 22, 2026, 4:00 PM EDT
74.63
-0.32 (-0.43%)
After-hours: May 22, 2026, 7:53 PM EDT
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $88.17. The average 1-year stock price forecast is 17.64% higher than the current stock price, while the lowest is $46 (-38.63%) and the highest is $110 (+46.76%).
Price Target: $88.17 (+17.64%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 5 | 5 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 4 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bernstein | Bernstein | Hold Maintains $35 → $46 | Hold | Maintains | $35 → $46 | -38.63% | May 13, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $80 → $87 | Buy | Maintains | $80 → $87 | +16.08% | May 8, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $88 | Buy | Initiates | $88 | +17.41% | May 1, 2026 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $78 → $100 | Hold → Buy | Upgrades | $78 → $100 | +33.42% | Apr 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +33.42% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
460.22M
from 829.45M
Decreased by -44.51%
Revenue Next Year
339.96M
from 460.22M
Decreased by -26.13%
EPS This Year
-3.40
from -0.01
EPS Next Year
-4.38
from -3.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 672.0M | 548.1M | ||||||
| Avg | 460.2M | 340.0M | ||||||
| Low | 306.7M | 111.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -19.0% | 19.1% | ||||||
| Avg | -44.5% | -26.1% | ||||||
| Low | -63.0% | -75.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.70 | -2.26 | ||||||
| Avg | -3.40 | -4.38 | ||||||
| Low | -4.00 | -6.57 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.